Drug Discovery World
DECEMBER 2, 2022
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas. Medlab’s NanaBis, to be used under NanaDol, a botanical version of NanaBis, has previously shown encouraging Phase I/II data for the treatment of cancer-induced bone pain and could be a potential alternative to opioids. .
Antidote
JULY 13, 2022
Before a potential new therapy can be administered to patients, it must go through several clinical trial phases designed to test the drug or device for safety and effectiveness. For many new treatments, it will take approximately ten years for the therapy to progress from initial discovery to being approved. Clinical trials alone take six to seven years on average to complete.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
APRIL 5, 2022
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…. The post The value of method of use patent claims in protecting your therapeutic assets appeared first on DrugPatentWatch - Make Better Decisions.
FDA Law Blog: Drug Discovery
DECEMBER 7, 2022
By Mark A. Tobolowsky & James E. Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Eye on FDA
JANUARY 26, 2022
FDA’s Office of Prescription Drug Promotion (OPDP) issued the first regulatory action letter for 2022. This one has some notable characteristics. As has been frequently noted, enforcement actions by OPDP have diminished considerably over the years. Another characteristic of recent enforcement actions over the past several years is that smaller, less well-known companies have mostly been the recipients of letters from OPDP.
ProRelix Research
DECEMBER 27, 2022
Clinical trials form the crux of all regulatory decisions regarding any new health intervention such as drugs and medical devices and thus require to be performed with the utmost care […]. The post USA Clinical Trial Market Size and Opportunities appeared first on ProRelix Research.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Conversations in Drug Development Trends
NOVEMBER 8, 2022
At Worldwide, we are committed to a cause that extends beyond ourselves. Our mission is to work with passion and purpose every day to improve lives. Our study teams are committed to working collaboratively with our sponsors, united in purpose. Worldwide aims to become an employer of choice?for veterans, military members, and?their families, by creating an?
Olympian Clinical Research
JUNE 10, 2022
Atopic dermatitis is a form of eczema and is the most common chronic inflammatory skin disease. While this condition is often seen in children, around 16.5 million Americans suffer from this itchy skin condition. Although there is no cure for this condition, with the proper knowledge, treatments, and lifestyle changes, those with eczema may manage their symptoms and lead happy, healthy lives.
Advarra
JULY 26, 2022
Cannabis use has become widespread. As such, we are seeing an uptick in research examining the therapeutic effects of cannabis and its constituents. Currently, cannabis use is legal across many states in the U.S., with 37 states approving medicinal use and 18 approving recreationally. However, it’s not legal federally and is considered a Schedule I drug by the U.S.
Drug & Device Law
MARCH 21, 2022
As we mentioned in last year’s comprehensive “ Survival of the Vaxxest ” blogpost on the constitutionality (for over a century) of governmental vaccine mandates, there is no appellate precedent requiring any sort of religious exemption to such mandates. Freedom of religion does not mean freedom to infect everyone else. While some jurisdictions allow exceptions to mandatory vaccination for “religious” reasons, that’s a matter of grace, not any sort of constitutional requirement.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Discovery World
DECEMBER 6, 2022
Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this; and highlights the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres to consider the overlap between
Antidote
DECEMBER 29, 2022
Generally, a doctor’s visit is intended to provide clarity and insight into a patient’s concerns — but many people are all too familiar with the feeling of walking out of a clinic more confused than when they arrived. In fact, many Americans find themselves searching for health literacy tips after becoming confused by a doctor’s instructions or the directions on a prescription label.
Drug Patent Watch
MARCH 22, 2022
FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…. The post DrugPatentWatch Week in Review appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery World
NOVEMBER 29, 2022
England will become the first country in Europe to roll out darolutamide (Nubeqa) to patients whose prostate cancer has spread to other parts of the body. . The drug works by blocking androgen receptors in cancer cells, which in turn blocks the effect of testosterone that allows the cancer cells to survive and multiply. Studies show the chances of living longer are increased by one third in men who were previously left untreated. .
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Discovery World
NOVEMBER 22, 2022
An Oxford University study has provided the first evidence that antibiotic resistant bacteria can travel from the gut to the lung, increasing the risk of deadly infections. . The findings coincide with World Antimicrobial Awareness Week and shed light on how antimicrobial resistance (AMR) arises and persists. . The study, which has been published in Nature Communications highlights the importance of preventing pathogenic bacteria from translocating from the gut to other organs where they can
Drug Discovery World
DECEMBER 14, 2022
A new study has demonstrated the ability of a novel peptide to selectively detect and neutralise an early molecular trigger of Alzheimer’s and other neurodegenerative diseases. . The Proceedings of the National Academy of Sciences (PNAS) will publish results of the groundbreaking study demonstrating a customised, synthetic peptide’s ability to selectively detect Alzheimer’s disease. .
Drug Discovery World
OCTOBER 27, 2022
Biotech company Mogling Bio has successfully has completed its first seed investment round with a sole investor, Kizoo Technology Capital. Mogling Bio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Ageing causes stem cells to lose their normal structure by increased activity of the protein CDC42. [.].
Drug Discovery World
OCTOBER 26, 2022
Kevin Holden. CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library?
Drug Discovery World
NOVEMBER 7, 2022
Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact. . The origins . One might argue that this all started getting exciting with the launch of the Human Genome Project, which the National Human Genome Research Institute consider to be one of the greatest scientifi
Drug Discovery World
OCTOBER 10, 2022
By Dr Dina Finan, PhD, Product Manager at 10x Genomics and Dr Nick Downey, PhD, NGS Collaborations Lead at Integrated DNA Technologies. RNA sequencing has become a widely used tool that can explore the transcriptome in a seemingly endless number of applications. While bulk sequencing—or sequencing the transcriptome of an entire sample at once—has contributed to many [.].
Drug Discovery World
NOVEMBER 24, 2022
With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . A new report by Charles River Associates for the European Federation of Pharmaceutical Industries and Associations (EFPIA has revealed that Europe is falling behind the US and Asia in its pharmaceutical R&D investment,
Drug Discovery World
SEPTEMBER 22, 2022
A new bioreactor platform that aims to support the cell and gene therapy (CGT) sector from process development to commercial manufacturing has been launched. The Quantum Flex Cell Expansion System has been created by medical technology company Terumo Blood and Cell Technologies (Terumo BCT). Using the system, developers can complete early process development on the same platform as manufacturing.
Drug Discovery World
SEPTEMBER 14, 2022
Nicola Richmond, VP of AI, BenevolentAI, will be speaking at the Tech Theatre, ELRIG Drug Discovery 2022, sponsored by DDW. Nicola Richmond is a mathematician with over 20 years’ experience of developing digital solutions to problems in drug discovery and development. She will be presenting a talk on ‘The lab of the future is now: Using AI or automation for the drug discovery process’ The Tech Theatre will feature a series of seminars focused on automation and technology for dr
Drug Discovery World
NOVEMBER 10, 2022
A new polymer-based drug delivery system for mRNA and other nucleic acids has won the CPHI Excellence in Pharma Award in the category “Packaging and Drug Delivery”. . The system was developed by Evonik Health Care together with researchers at Stanford University. . Developed together with Professors Robert Waymouth, Paul Wender and Ronald Levy from the University of Stanford in the US, the prize-winning polymer-based platform complements Evonik’s existing portfolio of lipid-based drug de
Drug Discovery World
AUGUST 30, 2022
The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. The event is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market.
Drug Discovery World
AUGUST 23, 2022
A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . The National Agency for Safety of Medicines and Health Products (ANSM) gave the go-ahead to Bayer AG to conduct the clinical trial through its subsidiary BrainVectis to investigate its gene therapy, BV-101 in the treatment for Huntington’s Disease (HD). .
Drug Discovery World
AUGUST 24, 2022
A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . Led by the University of Oxford, the PLATINUM study will investigate the use of Tecovirimat to see if it can help speed up the recovery of Monkeypox patients. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.
Drug Discovery World
AUGUST 9, 2022
Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments. . A team from The Institute of Cancer Research, London discovered that melanoma cells harness a gene usually used by growing nerves to escape from their immediate area and invade new tissues. . They found that melanoma cells use the gene ARHGEF9 to create ‘molecular drills’ which help them attach to, and punch holes through, surrounding cells and structures.?
Drug Discovery World
OCTOBER 14, 2022
Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalised cancer treatment used in combinati
Drug Discovery World
JULY 11, 2022
Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US. . Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The company plans to work with clinical research organisation (CRO) Veristat to deliver its programmes. .
Drug Discovery World
OCTOBER 3, 2022
Join Anne Hammerstein, Ph.D., Product Manager at SPT Labtech, for a fascinating deep dive into the practical considerations of how, when and why you should automate your laboratory’s liquid handling processes. The talk will take place at ELRIG’s Drug Discovery 2022 Tech Theatre, supported by DDW. The event will take place on 4-5 Oct, London Excel, UK and topics will include: The lab of the future is now.
Drug Discovery World
NOVEMBER 23, 2022
Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The breakthrough research may offer fresh hope in tackling currently untreatable conditions such as Alzheimer’s disease (AD). . The study was led by researchers at the University of Glasgow’s new Advanced Research Centre (ARC) and published in Science Signaling.
Drug Discovery World
NOVEMBER 16, 2022
DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. .
Drug Discovery World
NOVEMBER 17, 2022
Algorithmiq, a Helsinki-based quantum computing start-up, has entered into an engagement with IBM to progress in its exploration of quantum algorithms that attempt to solve complex issues in life sciences. . Between IBM’s hardware, software and quantum applications expertise and Algorithmiq’s algorithm developers, the companies hope to explore ways to dramatically cut the time and cost of drug discovery and development. .
Expert insights. Personalized for you.
246 
Let's personalize your content